Company

Bank

Analyst

Coverage

Opinion

Wk chg

5/16 cls

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)

Summer Street

Jim Molloy

New

Buy

19%

$280.26

Molloy initiated coverage with a $650 target ahead of potential catalysts for Intercept's lead product obeticholic acid. He said the Phase II FLINT trial with OCA to treat non-alcoholic steatohepatitis (NASH) was stopped early in January due to "massive efficacy" (see BioCentury, Jan. 13). Full FLINT data will be presented in July. Intercept also plans to submit an NDA to FDA by year end for the oral farnesoid X receptor (FXR; NR1H4) agonist to treat primary biliary cirrhosis (PBC). Molloy expects FDA approval for PBC in 4Q15.